News Archive

Necessary

Always Enabled

Non Necessary

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_46834490_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.

News

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

Caring for the Caregiver

FDA Approves Kaléo’s Naloxone Auto-Injector 10 mg for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids

Marathon Asset Management Announces Acquisition of Kaléo

Kaléo Expands Executive Team with New Appointments

The Upcoming School Year is Expected to be Fraught with Uncertainty, Particularly for Children with Life-Threatening Food Allergies

Kaléo and the pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® (epinephrine injection, USP) Auto-Injector for the Treatment of Serious Allergic Reactions Across Canadian Provinces

Kaléo et l’Alliance pancanadienne pharmaceutique (APP) concluent leurs négociations sur l’auto-injecteur ALLERJECT® (épinéphrine injectable, USP) destiné au traitement des réactions allergiques graves dans les différentes provinces canadiennes.

Kaléo Announces ALLERJECT® (epinephrine injection, USP) Auto-Injector Will Be Available for Canadians at Risk for Anaphylaxis Starting May 19, 2020

Kaléo annonce qu’à partir du 19 mai 2020 l’auto-injecteur ALLERJECT® (épinéphrine injectable, USP) sera à la disposition des Canadiens à risque d’anaphylaxie.

Walgreens and Kaléo Expand Retail Pharmacy Collaboration to Include AUVI-q® (epinephrine injection, USP) 0.1 mg, the Only FDA-Approved Epinephrine Auto-Injector for Infants and Toddlers, 16.5 – 33 lbs

Authorized Generic for EVZIO® (naloxone HCl injection) to be Available at a Reduced List Price of $178

Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues, Providing Patients Access to AUVI-Q® (epinephrine injection, USP) Through Walgreens Locations Nationwide

AUVI-Q® (epinephrine injection, USP) Available in Canada Starting September 7

Kaléo Confirms U.S. Availability of AUVI-Q® (epinephrine injection, USP) Auto-injector for Back-to-School Season

With Life-Threatening Allergies Diagnosed in Infancy, Kaléo Announces Availability of First and Only FDA-Approved Epinephrine Auto-Injector (EAI) for Infants and Toddlers Weighing 16.5 to 33 Pounds (7.5 to 15 kilograms)

NASCAR Driver Elliott Sadler Teams Up with Kaléo about AUVI-Q® (Epinephrine Injection, USP) to Raise Awareness of Life-Threatening Allergies

EVZIO® (naloxone HCl injection, USP) Auto-Injector Now Available to Patients in Select States Without a Prescription Through Kaléo’s New Virtual Standing Order Pilot Program and to Government Agencies at a Direct Purchase Price

How Can We Help You?